Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156919 | 0.86 | HPGD (0.59) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3583010 | 0.85 | CA1 (0.52) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL14185215 | 0.81 | MAPT (0.48) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2184783 | 0.81 | KDM4E (0.62) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2331243 | 0.79 | ALDH1A1 (0.45) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2334482 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL14185196 | 0.77 | KDM4E (0.57) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL12413335 | 0.76 | KDM4E (0.56) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2332179 | 0.73 | ALDH1A1 (0.44) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL7007893 | 0.73 | ELANE (0.66) | ALDH1A1MAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717706-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC | 2015-12-10 | — | — | US | disclosed |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2533637-B1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8669381-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8481590-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2533637-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011099978-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ALDH1A1 363/4885MAPT 3897/4885KMT2A 3462/4885 |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ALDH1A1 363/4885MAPT 3897/4885KMT2A 3462/4885 |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ALDH1A1 363/4885MAPT 3897/4885KMT2A 3462/4885 |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ALDH1A1 363/4885MAPT 3897/4885KMT2A 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.